SCHEMBL5428129

SCHEMBL5428129

C1CNCC2(C1)CNCCNC2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 8/20 0.41
CYP3A4 P08684 8/20 0.41
ALDH1A1 P00352 8/20 0.41
CYP1A2 P05177 5/20 0.41
USP2 O75604 4/20 0.41
HSD17B10 Q99714 5/20 0.40
TSHR P16473 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
CXCR4 P61073 1/20 0.39
CYP2C9 P11712 2/20 0.38
MAPK1 P28482 4/20 0.37
CYP2C19 P33261 3/20 0.37
HPGD P15428 2/20 0.37
TP53 P04637 2/20 0.37
CHEK1 O14757 1/20 0.33
AURKA O14965 1/20 0.33
RPS6KA5 O75582 1/20 0.33
CHEK2 O96017 1/20 0.33
ABL1 P00519 1/20 0.33
LCK P06239 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1545685 0.94
SCHEMBL5421687 0.91 ALDH1A1 (0.37) CYP2D6CYP3A4ALDH1A1CYP1A2USP2
SCHEMBL165883 0.90 CYP2D6 (0.42) CYP2D6CYP3A4ALDH1A1CYP1A2USP2
SCHEMBL5428077 0.88 CYP2D6 (0.39) CYP2D6CYP3A4ALDH1A1CYP1A2USP2
SCHEMBL1796659 0.88
SCHEMBL347193 0.88
SCHEMBL1793924 0.88 CYP2D6 (0.41) CYP2D6CYP3A4ALDH1A1CYP1A2USP2
Hydrochloric Acid SCHEMBL10621465 0.88 CYP2D6 (0.41) CYP2D6CYP3A4ALDH1A1CYP1A2USP2
Water SCHEMBL6402454 0.88 CYP3A4 (0.41) CYP2D6CYP3A4ALDH1A1CYP1A2USP2
SCHEMBL5427276 0.85 ALDH1A1 (0.37) CYP2D6CYP3A4ALDH1A1CYP1A2USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275990-A1 Heterocyclic Spiro Compound ONO PHARMACEUTICAL CO., LTD. 2007-11-29 US disclosed
EP-1683797-A1 HETEROCYCLIC SPIRO COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2006-07-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275990-A1 Heterocyclic Spiro Compound NR3C2, CBR1, CBR3 CYP2D6 208/4885CYP3A4 888/4885ALDH1A1 718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.